HALOZYME THERAPEUTICS, INC. 8K

Halozyme Therapeutics reported record Q2 2026 results, announced multiple new collaboration agreements, increased its share repurchase activity, and raised full‑year 2026 financial guidance for revenue, earnings and EBITDA.

On August 6, 2026, Halozyme Therapeutics, Inc. reported record financial results for the second quarter ended June 30, 2026, highlighted by a 48% year-over-year increase in total revenue to $481 million, a 50% increase in royalty revenue to $308 million, strong profitability metrics including GAAP diluted EPS of $1.90 and non-GAAP diluted EPS of $2.28, and raised full‑year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA, and non‑GAAP EPS. The company also detailed extensive business development activity, noting five new ENHANZE and Hypercon collaboration and license agreements year‑to‑date 2026 with partners including Vertex, Oruka Therapeutics, GSK, Incyte and an undisclosed nucleic acid therapeutic partner, as well as positive pipeline and regulatory developments from existing partners such as Janssen, argenx, Takeda and Viatris. In capital allocation, Halozyme highlighted a May 2026 authorization of a new share repurchase program of up to $1.0 billion through December 31, 2028 and disclosed that it repurchased approximately 4.8 million shares for $332.8 million during the second quarter under its May 2026 and February 2024 programs, completing the latter in June 2026. Management emphasized the durability and diversification of royalty revenues from ENHANZE and the expansion of its drug delivery technology portfolio, including Hypercon and Surf Bio’s hyperconcentration technology, as key drivers of both near‑term performance and long‑term growth expectations, and provided updated 2026 guidance ranges of $1.835–$1.910 billion in total revenue, $1.220–$1.245 billion in royalty revenue, $1.225–$1.280 billion in adjusted EBITDA, and non‑GAAP diluted EPS of $8.65–$9.00.

Filing Facts

CIK

1159036

Ticker

HALO

Form

8K

Source Type

fda

Accession

0001159036-26-000103

Alert Tier

7